Rory B. Riggs - Jun 25, 2021 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Role
Director
Signature
/s/ Jason Mehar, as Attorney-in-Fact for Rory B. Riggs
Stock symbol
RPRX
Transactions as of
Jun 25, 2021
Transactions value $
-$55,370,134
Form type
4
Date filed
6/29/2021, 08:31 PM
Previous filing
Jun 22, 2021
Next filing
Jul 2, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPRX Class A Ordinary Shares Sale -$7.67M -179K -16.09% $42.81 934K Jun 25, 2021 By New Ventures Select F1
transaction RPRX Class A Ordinary Shares Sale -$20.8M -487K -10.62% $42.69 4.1M Jun 25, 2021 By New Ventures I LLC F2
transaction RPRX Class A Ordinary Shares Sale -$7.05M -167K -4.08% $42.11 3.93M Jun 28, 2021 By New Ventures I LLC F3
transaction RPRX Class A Ordinary Shares Sale -$50.4K -1.2K -0.03% $42.01 3.93M Jun 29, 2021 By New Ventures I LLC F4
transaction RPRX Class A Ordinary Shares Sale -$19.8M -480K -12.21% $41.26 3.45M Jun 29, 2021 By New Ventures I LLC F5
holding RPRX Class A Ordinary Shares 680K Jun 25, 2021 Direct
holding RPRX Class A Ordinary Shares 2.08M Jun 25, 2021 By New Ventures III LLC
holding RPRX Class A Ordinary Shares 15K Jun 25, 2021 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.44 to $43.29 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.33 to $43.04 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.90 to $42.79 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.03 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.87 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.